Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 261

1.

Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

Eddy DM, Schlessinger L, Kahn R.

Ann Intern Med. 2005 Aug 16;143(4):251-64.

PMID:
16103469
[PubMed - indexed for MEDLINE]
2.

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group.

Ann Intern Med. 2005 Mar 1;142(5):323-32.

PMID:
15738451
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Summaries for patients. The outcomes and costs of diabetes prevention with a diet and exercise program or metformin: a computer model.

[No authors listed]

Ann Intern Med. 2005 Aug 16;143(4):I22. No abstract available.

PMID:
16103465
[PubMed - indexed for MEDLINE]
4.

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.

Diabetes Prevention Program Research Group.

Diabetes Care. 2003 Sep;26(9):2518-23.

PMID:
12941712
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
7.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

PMID:
15147610
[PubMed - indexed for MEDLINE]
Free Article
8.

The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.

Diabetes Prevention Program Research Group.

Diabetes Care. 2012 Apr;35(4):723-30. doi: 10.2337/dc11-1468. Erratum in: Diabetes Care. 2013 Dec;36(12):4173-5.

PMID:
22442395
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.

Palmer AJ, Tucker DM.

Prim Care Diabetes. 2012 Jul;6(2):109-21. doi: 10.1016/j.pcd.2011.10.006. Epub 2011 Dec 6.

PMID:
22153888
[PubMed - indexed for MEDLINE]
10.

Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore.

Png ME, Yoong JS.

PLoS One. 2014 Sep 9;9(9):e107225. doi: 10.1371/journal.pone.0107225. eCollection 2014.

PMID:
25203633
[PubMed - in process]
Free PMC Article
11.

Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.

Herman WH, Edelstein SL, Ratner RE, Montez MG, Ackermann RT, Orchard TJ, Foulkes MA, Zhang P, Saudek CD, Brown MB; Diabetes Prevention Program Research Group.

Am J Manag Care. 2013;19(3):194-202.

PMID:
23544761
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].

Flórez H.

Invest Clin. 1997 Mar;38(1):39-52. Review. Spanish.

PMID:
9235072
[PubMed - indexed for MEDLINE]
13.

Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.

Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, Giani G; KORA Study Group.

Diabet Med. 2007 May;24(5):473-80. Epub 2007 Mar 22.

PMID:
17381502
[PubMed - indexed for MEDLINE]
14.
15.

Achievable cost saving and cost-effective thresholds for diabetes prevention lifestyle interventions in people aged 65 years and older: a single-payer perspective.

Anderson JM.

J Acad Nutr Diet. 2012 Nov;112(11):1747-54. doi: 10.1016/j.jand.2012.08.033.

PMID:
23102174
[PubMed - indexed for MEDLINE]
16.

Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.

Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA.

Curr Med Res Opin. 2004 Aug;20 Suppl 1:S41-51.

PMID:
15324515
[PubMed - indexed for MEDLINE]
17.

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.

Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM.

Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Erratum in: Lancet. 2009 Dec 19;374(9707):2054.

PMID:
19878986
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.

Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM; Diabetes Prevention Program Research Group.

Diabetes Care. 2003 Jan;26(1):36-47.

PMID:
12502656
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

Lee WC, Samyshkin Y, Langer J, Palmer JL.

J Med Econ. 2012;15 Suppl 2:28-37. doi: 10.3111/13696998.2012.716111. Epub 2012 Aug 13.

PMID:
22834986
[PubMed - indexed for MEDLINE]
20.

Screening for type 2 diabetes: literature review and economic modelling.

Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A.

Health Technol Assess. 2007 May;11(17):iii-iv, ix-xi, 1-125. Review.

PMID:
17462167
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk